1
|
Montanari L, Mazzilli S, Tarján A, Hasselberg I, Hall W, Vandam L, Vernooij A, Stöver H. Overview of availability of harm reduction interventions in European prisons. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac129.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Prisons are high-risk environments for the transmission of drug related infections, due to over-incarceration of people who inject drugs; often inadequate healthcare, substandard prison conditions; and others. An overview of the availability and coverage of prison-based harm reduction interventions in Europe is presented.
Methods
National Focal Points of the EMCDDA (30) collected 2019 data, which were integrated with findings from the European funded project HA-REACT (Joint Action on HIV and Co-infection Prevention and Harm Reduction).
Results
Prison based harm reduction interventions are available in European countries, but only few of them are available in most countries and often with a low coverage (e.g. less than 10% of prison population in Opioid Substitution Treatment (OST) in most countries). Interventions available in most countries (20 or more) include: HIV, HBV, HCV testing (29), OST continued from community (29), Referral to HIV treatment upon release (28), HIV treatment (27), Referral to HCV treatment upon release (25), HCV antiviral treatment (25), Testing for TB (23), HBV antiviral therapy (25), OST initiated in prison (22), Treatment for TB (21), Vaccination for HBV (20). Interventions available in 10 to 19 countries are: condom distribution (19), OST (re)initiated before release (17), prison/community guidelines for implementation of OST (13). Interventions provided in < 10 countries include: distribution of disinfectant (9), condom with lubricant (9), take-home naloxone (5), needles and syringes programs (3).
Conclusions
Compared to the community, the availability and coverage of harm reduction interventions in European prisons are limited and large information gaps exist. Scaling up harm reduction in prison can achieve important individual and public-health benefits.
Collapse
Affiliation(s)
- L Montanari
- Public Health Unit, EMCDDA , Lisbon, Portugal
| | - S Mazzilli
- Department of Translational Research in Medicine, University of Pisa , Pisa, Italy
- Scuola Normale Superiore , Pisa, Italy
| | - A Tarján
- Hungarian Reitox National Focal Point , Budapest, Hungary
| | - I Hasselberg
- Centre for Research in Anthropology, University of Minho , Braga, Portugal
| | - W Hall
- National Centre for Youth Substance Use, The University of Queensland , Brisbane, Australia
| | - L Vandam
- Public Health Unit, EMCDDA , Lisbon, Portugal
| | - A Vernooij
- Public Health Unit, EMCDDA , Lisbon, Portugal
| | - H Stöver
- Institute of Addiction Research, University of Applied Sciences , Frankfurt am Main, Germany
| |
Collapse
|
2
|
Canellas M, Jewell M, Olivier D, Edwards J, Jun-O'Connell A, Hall W, Reznek M. 411EMF Measurement of Cost of Boarding Code Stroke Patients in the Emergency Department Using Time-Driven Activity-Based Costing. Ann Emerg Med 2022. [DOI: 10.1016/j.annemergmed.2022.08.428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
3
|
Nguyen P, Liu V, Proudfoot J, Davicioni E, Liu Y, Dal Pra A, Spratt D, Sandler H, Efstathiou J, Lawton C, Simko J, Rosenthal S, Zeitzer K, Mendez L, Hartford A, Hall W, Desai A, Pugh S, Tran P, Feng F. 1378P Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
4
|
Chakrabarti S, Benrud R, Chau J, Hall W, Shreenivas A, Erickson B, Peterson C, Ridolfi T, Miller J, Banerjee A, Thomas J, Sharif S, Fei N, Ludwig K, Olshan P, Palsuledesai C, Malhotra M, Jurdi A, Aleshin A, Kasi P. P-39 Utility of circulating tumor DNA (ctDNA) to assess tumor response in patients with locally advanced rectal cancer undergoing neoadjuvant therapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
5
|
Sritharan K, Akhiat H, Cahill D, Choi S, Choudhury A, Chung P, Diaz J, Dysager L, Hall W, Kerkmeijer L, Lawton C, Murray J, Nyborg C, Pos F, Rigo M, Schytte T, Sidhom M, Sohaib A, Tan A, van der Voort van Zyp J, Vesprini D, Zelefsky M, Tree A. PD-0571 Determining interobserver variability in prostate bed CTV target delineation using MRI. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02886-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Westerhoff J, Daamen L, Christodouleas J, Blezer E, Choudhury A, Westley R, Erickson B, Fuller C, Hafeez S, van der Heide U, Intven M, Kirby A, Lalondrelle S, Minsky B, Mook S, Nowee M, Marijnen C, Orrling K, Sahgal A, Schultz C, Tersteeg R, Tree A, Tseng C, van der Voort van Zyp J, Verkooijen H, Hall W. OC-0419 Patterns of Care and Safety in 1800 patients treated on a high-field MR-Linac platform registry. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02555-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Eijkelenkamp H, Grimbergen G, Heerkens H, Meijer G, Daamen L, Molenaar Q, van Santvoort H, Erickson B, Hall W, Intven M. MO-0221 Short-term toxicity outcomes after MR-guided SBRT for (peri-)pancreatic tumors on a 1.5T MR-linac. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02323-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Gough J, Hall W, Good J, Nash A, Aitken K. Technical Radiotherapy Advances – The Role of Magnetic Resonance Imaging-Guided Radiation in the Delivery of Hypofractionation. Clin Oncol (R Coll Radiol) 2022; 34:301-312. [DOI: 10.1016/j.clon.2022.02.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 02/07/2022] [Accepted: 02/23/2022] [Indexed: 12/30/2022]
|
9
|
Sundar S, Biggs S, Abraham M, Cook J, Watts N, Price R, Brack M, Brown N, Dixon L, Crowther O, Trenaman R, Quinn D, Hall W, Younie S. 1232 Trust-Wide Assessment of Delirium in Post-Operative Elective Surgery. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Aim
Delirium is an acute change in cognition and associated with adverse patient outcomes. The incidence of post-operative delirium after elective non-cardiac surgery is unknown. We aimed to assess the incidence of post-operative delirium in this group and the effect on patient outcomes.
Method
Patients aged 65 and over who underwent elective non-cardiac surgery were identified on post-operative day three. Delirium screening was performed in real time using the validated 4-AT assessment tool. A retrospective review of the patients’ preoperative and perioperative record was conducted to collect demographics and identify risk factors for delirium. Outcome data was collected at 30 days. Patients with a positive delirium score (>4) underwent a more in-depth assessment and managing teams given a delirium management pack.
Results
75 (39 male) consecutive patients were screened over a period of 4 months. Median age 77 years and 18% had frailty assessed as “vulnerable”. The majority of patients (37.3%) underwent thoracic surgery, followed by hepatobiliary (17.3%), gynaecological (17.3%), colorectal (12%), maxillofacial (9.3%) and ENT (4%). 5.3% (4) of patients had a positive 4-AT screen. No patients had a formal delirium screen or diagnosis in the initial 48 hours. The median length of stay for patients with a positive screen was 8.5 days (IQR 7.5-12) compared to 8 days (IQR 5-13) for patients with a negative screen.
Conclusions
Reassuringly, rate of post-operative delirium following elective operations in our Trust are low (5%). Larger numbers of patients are required to assess the impact this has on patient outcomes and identify correlation with risk factors.
Collapse
Affiliation(s)
- S Sundar
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - S Biggs
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - M Abraham
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - J Cook
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - N Watts
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - R Price
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - M Brack
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - N Brown
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - L Dixon
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - O Crowther
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - R Trenaman
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - D Quinn
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - W Hall
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - S Younie
- Bristol Royal Infirmary, Bristol, United Kingdom
| |
Collapse
|
10
|
Daamen L, de Mol van Otterloo S, van Goor I, Eijkelenkamp H, Erickson B, Hall W, Heerkens H, Meijer G, Molenaar Q, van Santvoort H, Verkooijen L, Intven M. PO-1218 Online adaptive MR-guided SBRT for unresectable upper abdominal malignancies using a 1.5T MR-linac. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07669-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Zaidman-Zait A, Hall W. Contributions of parents' reports of children's sleep and challenging family contexts at age five to teachers' reports of children's classroom engagement and academic achievement two years later. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Kaufman CS, Behrndt VS, Hall W, Moses K, Wolgamot GM, Crabo L, Backer L, Carpenter K, Smits S. Abstract P5-02-02: Improving efficiency of breast MRI utilization by coordinating primary care, breast imaging and surgeons. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-02-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Breast MRI in the workup of a new breast cancer diagnosis is both a valuable and costly imaging study. The decision to obtain a breast MRI is often made by the surgeon who is referred the newly diagnosed breast cancer patient. That is followed by a delay in their management due to scheduling the MRI. Our breast center program leadership developed a protocol to move the time of MRI prior to the surgeon's evaluation while avoiding unnecessary breast MRIs ordered by some well-intentioned primary care providers. Coordinating a breast MRI protocol can optimize timely performance of breast MRI, guiding primary care to become the ordering clinician while avoiding unnecessary breast MRIs.
Methods: Recognizing a delay in the journey of newly diagnosed breast cancer patients that have their breast MRI ordered only after the multidisciplinary conference or surgical consultation, we developed a protocol to improve timeliness of care. Guidelines were identified by our breast program leadership when a newly diagnosed breast cancer patient would warrant a breast MRI. Agreed upon indicators included dense breast tissue, invasive lobular breast cancer, patients typically under 50 years old, and vague imaging of primary lesions. When these findings were identified, the radiologist included a statement with the core needle biopsy report. It stated that our breast program leadership identified this patient as benefiting from a breast MRI ordered soon after the positive biopsy. This avoided the issue of self-referral since our breast leadership created the guidelines. The message went to the primary care provider who now ordered the breast MRI prior to conference or surgical consultation. We examined sixty consecutive patients from two time periods, half before and half after institution of the MRI protocol.
Results: Prior to this policy, patients who needed breast MRI would obtain the study on average 12 days after our multidisciplinary breast conference (MDC), while after institution of the policy breast MRI was obtained 3 days PRIOR to conference. Before only 43% of necessary breast MRIs were ordered prior to surgical consultation while after the protocol 100% of breast MRIs were ordered PRIOR to surgical consultation. Before the protocol rarely did primary care order breast MRIs. After the protocol primary care providers ordered 80% of all breast MRIs. While ordering more breast MRIs, primary care ordered less unnecessary studies. After the protocol was instituted, inappropriate studies as determined by the MDC decreased from 21% deemed unnecessary to only 10%.
Conclusions: Institution of a breast MRI ordering guideline by the breast program leadership with participation of primary care had the benefits of obtaining the breast MRI before the multidisciplinary conference and/or surgical consultation while avoiding unnecessary breast MRI orders. Institution of a breast MRI protocol enhances patient care, eliminates delays in treatment, avoids unnecessary tests, shifts appropriate care to primary care providers and allows initial surgical consultation to have all the data necessary to make definitive decisions. This quality improvement effort via program leadership improved comprehensive care.
Citation Format: Kaufman CS, Behrndt VS, Hall W, Moses K, Wolgamot GM, Crabo L, Backer L, Carpenter K, Smits S. Improving efficiency of breast MRI utilization by coordinating primary care, breast imaging and surgeons [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-02-02.
Collapse
Affiliation(s)
- CS Kaufman
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - VS Behrndt
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - W Hall
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - K Moses
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - GM Wolgamot
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - L Crabo
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - L Backer
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - K Carpenter
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| | - S Smits
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; PeaceHealth Cancer Center, Bellingham, WA; Northwest Pathology, Bellingham, WA
| |
Collapse
|
13
|
Gordon J, Ammendolea C, Chari N, Armstrong R, Hall W. Abstract P5-13-10: Recommendations to improve the lived experience of early stage and metastatic breast cancer patients in Canada. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-13-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: In 2017, the Canadian Breast Cancer Network (CBCN) undertook two surveys of Canadians who have experienced a breast cancer diagnosis to better understand the lived experience of patients and what opportunities exist to improve support for patients, survivors and their families and minimize the impact of this disease. There were 278 people diagnosed with early stage breast cancer, defined as stage I, II or III for the purpose of this report, and 180 people living with metastatic breast cancer, or stage IV breast cancer, who responded to these surveys.
Results: The survey data shows that while patients feel supported and well cared for in certain aspects there are still significant opportunities for improvement. CBCN has identified five overarching factors that could greatly improve health outcomes and the quality of life of Canadians who experience a breast cancer diagnosis.
1. Improved Educational Resources: The quality and availability of patient education has increased over the past couple of decades; however, there are still some patient friendly educational resources including, specific resources for newly diagnosed metastatic breast cancer patients; decision aids that support breast cancer surgery and post-surgery decisions; navigation of financial resources; treatment timelines and recovery expectations; private insurance navigation and information on dying-well.
2. Increased Access to Treatments: This challenge was specifically identified and vocalized by people living with metastatic breast cancer. Efforts need to continue to shorten the drug approval process time, increase equitable access to new medications for all Canadians, and ensure equitable access for take home oral cancer medications.
3. Increased Access to Information: Information available to patients about their health and treatment has increased; however, there is still information that isn't always communicated to patients that would help them make informed decisions about their health. This includes information about breast density, palliative care options and information around clinical trials.
4. Integrated Systemic Supports: The health care system as a whole is responsible for many of the services and supports that patients need to achieve optimal health and manage their breast cancer; however, these supports can be challenging to navigate and are sometimes lacking. Supports that need to be addressed at a systemic level include developing survivorship care plans for early stage patients, patient navigation, communication tools to support general practitioners during the diagnosis process, access to psychosocial professionals and increased Employment Insurance Sickness Benefits.
5. Increased Awareness and Understanding of Metastatic Breast Cancer: A lack of accurate statistics and overall awareness of metastatic breast cancer makes it challenging to truly understand the impact of this disease and also leaves people living with an incurable form of breast cancer feeling isolated and disconnected. Accurate statistics and increased awareness would help further the understanding of the impact of this stage of breast cancer and better support those with it.
Citation Format: Gordon J, Ammendolea C, Chari N, Armstrong R, Hall W. Recommendations to improve the lived experience of early stage and metastatic breast cancer patients in Canada [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-13-10.
Collapse
Affiliation(s)
- J Gordon
- Canadian Breast Cancer Network, Ottawa, ON, Canada
| | - C Ammendolea
- Canadian Breast Cancer Network, Ottawa, ON, Canada
| | - N Chari
- Canadian Breast Cancer Network, Ottawa, ON, Canada
| | - R Armstrong
- Canadian Breast Cancer Network, Ottawa, ON, Canada
| | - W Hall
- Canadian Breast Cancer Network, Ottawa, ON, Canada
| |
Collapse
|
14
|
Kaufman CS, Hall W, Behrndt VS, Wolgamot GM, Zacharias K, Rogers A, Smith A, Hill LM, Schnell N. Abstract P5-16-02: Enhance post-lumpectomy breast contour using oncoplastic surgery (OPS) plus a bioabsorbable 3-D tissue implant. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-16-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The appearance after breast surgery has become an important aspect of survivorship. The post lumpectomy/post radiation hollow surgical defect negatively impacts cosmesis and patient satisfaction. Oncoplastic procedures will mobilize surrounding tissues into the lumpectomy cavity but adds no volume to the breast. Use of a bioabsorbable 3-dimensional tissue implant (used for targeting radiation) has the additional benefit of adding volume to the breast and enhances the overall cosmetic appearance. Our experience over 3 years provides serial mammograms from which we may objectively categorize cosmetic contour. We report on our 2 and 3 year serial images of our treated patients compared with baseline.
Methods: Between May 2014 and June 2018, during lumpectomy for breast cancer we implanted a 3-D tissue implant marker in 170 patients, often combined with oncoplastic reconstruction and followed by radiation treatment. For long term follow-up we had 37 patients with serial mammograms at 2 or 3 years to assess cosmesis. All patients had interviews, physical exams, and serial mammograms to evaluate their cosmetic appearance. Both physician and patient graded their appearance. We also objectively measured and compared the pre-treatment mammogram and the 2-year and 3-year, post-treatment mammogram for symmetry and size using each breast as its own control. Using the post-treatment mammograms, we compared the relative anterior-posterior (depth) measurement of the quadrant bearing the implant as well as the non-cancer quadrant to the similar locations of the pre-treatment mammogram. Both mammogram positioning and radiation effects would balance. We compared the relative change from baseline in the non-cancer portion of the breast to the change from baseline in the cancer portion of the breast as a percent difference from baseline.
Results: Patients were treated with lumpectomy, oncoplastic reconstruction, and placement of a 3-D tissue implant. Three implants were removed due to positive margins. No implants were removed for any other reason. There have been no local recurrences. Overall, radiation oncologists felt the 3-D implant was useful for treatment planning in 85% of patients. Of the 37 consecutive patients who have completed an average of 27.8 months of follow-up, cosmesis was rated as excellent/good by clinicians (96%) and patients (94%). Mammograms taken at 2-3 years were compared with initial images. Whole-breast radiation effect varied among patients. Some had significant shrinkage while others had none. These changes were equal in the non-cancer post-radiation quadrants (86.2% vs 87%) demonstrating maintenance of normal breast contour. Our use of the 3-D implant and oncoplastic tissue advancement maintained the pre-operative contour of the breast after lumpectomy with radiation.
Conclusions: Breast cancer surgery and radiation is often complicated by poor cosmesis with retraction and volume loss. Using a combination of oncoplastic surgery combined with a 3-D tissue implant, we found the forward projection and contour of the breast at the lumpectomy site was preserved and patient satisfaction was good to excellent. Further investigation of the long-term cosmetic effects of breast cancer surgery should be encouraged.
Citation Format: Kaufman CS, Hall W, Behrndt VS, Wolgamot GM, Zacharias K, Rogers A, Smith A, Hill LM, Schnell N. Enhance post-lumpectomy breast contour using oncoplastic surgery (OPS) plus a bioabsorbable 3-D tissue implant [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-02.
Collapse
Affiliation(s)
- CS Kaufman
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - W Hall
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - VS Behrndt
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - GM Wolgamot
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - K Zacharias
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - A Rogers
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - A Smith
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - LM Hill
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - N Schnell
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| |
Collapse
|
15
|
Ammendolea C, Gordon J, Hall W, Armstrong R, Chari N. Financial Resources Digital Navigation Tool for Metastatic Breast Cancer Patients. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.69400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background and context: Although Canadians enjoy a universal health care system, there continues to be costs to patients that are not covered by the system. The economic impact of breast cancer is huge and, in many cases, devastating for patients and their families. As a result there is a need for educational and navigational resources that assist patients with the financial burden of facing a metastatic breast cancer diagnosis. Aim: The aim of this project is to develop an online navigation tool that will assist Canadians living with metastatic breast cancer source financial supports and resources to help lessen the financial impact of their diagnosis. Strategy/Tactics: An advisory board of people living with metastatic breast cancer was convened to help guide this project and provide input on the lived experience and financially challenges of Canadians living with this stage of the disease. The input from the advisory board along with the responses from a survey of over 150 Canadian metastatic breast cancer patients informed the type of information that should be included in the resource. Through an environmental scan and research of various financial supports, a comprehensive list of financial resources available locally, regionally and nationally was compiled. This data were integrated into a database that will be accessed through an intuitive online interface that will be integrated with CBCN´s Web site. The advisory board reviewed the draft content and framework to ensure that identified needs and priorities have been addressed. All content was translated into French as this tool will be offered in both French and English. The anticipated launch of this resource is November 2018. Outcomes: CBCN anticipates that over 1200 people living with metastatic breast cancer will access this resource in the first year and that over 50 institutions will be informed that this tool is available for their patients. Given that this will be a unique resource, CBCN expects that patients, health care professionals and support workers will access this resource to better support people living with metastatic breast cancer. What was learned: This resource has not launched, but based on CBCN´s research and the feedback of the patient advisory board, it is understood that there is a great need for this financial resources navigation tool.
Collapse
|
16
|
Orba Y, Hang'ombe BM, Mweene AS, Wada Y, Anindita PD, Phongphaew W, Qiu Y, Kajihara M, Mori-Kajihara A, Eto Y, Sasaki M, Hall WW, Eshita Y, Sawa H. First isolation of West Nile virus in Zambia from mosquitoes. Transbound Emerg Dis 2018; 65:933-938. [PMID: 29722174 DOI: 10.1111/tbed.12888] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Indexed: 11/28/2022]
Abstract
Mosquito surveillance studies to identify mosquito-borne flaviviruses have identified West Nile Virus (WNV) for the first time in Zambia. The Zambian WNV isolate from Culex quinquefasciatus mosquitoes collected in the Western Province was closely related genetically to WNV lineage 2 South African strains which have been previously shown to be highly neuroinvasive. These data provide the first evidence of the circulation of WNV in Zambia and suggest there should be an increased awareness of possible associated human and animal diseases in that country.
Collapse
Affiliation(s)
- Y Orba
- Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - B M Hang'ombe
- Department of Paraclinical Studies, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| | - A S Mweene
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia
| | - Y Wada
- Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - P D Anindita
- Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - W Phongphaew
- Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - Y Qiu
- Hokudai Center for Zoonosis Control in Zambia, Lusaka, Zambia
| | - M Kajihara
- Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - A Mori-Kajihara
- Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - Y Eto
- Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - M Sasaki
- Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - W W Hall
- Centre for Research in Infectious Diseases, University College Dublin, Dublin, Ireland.,Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan.,Global Virus Network, Baltimore, Maryland, USA
| | - Y Eshita
- Hokudai Center for Zoonosis Control in Zambia, Lusaka, Zambia
| | - H Sawa
- Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.,Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan.,Global Virus Network, Baltimore, Maryland, USA
| |
Collapse
|
17
|
Rigney G, Weiss S, Chambers C, Godbout R, Gruber R, Hall W, Reid G, Stremler R, Witmans M, Begum E, Corkum P. Better nights, better days: relative success of digital, media and traditional recruitment methods for an e-health intervention for children with behavioural insomnia. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.1017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Cullen A, Barnett A, Komesaroff P, Brown W, O'Brien K, Hall W, Carter A. A qualitative study of overweight and obese Australians' views of food addiction. Appetite 2017; 115:62-70. [DOI: 10.1016/j.appet.2017.02.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 01/31/2017] [Accepted: 02/08/2017] [Indexed: 12/25/2022]
|
19
|
Kaufman CS, Hall W, Behrndt V, Wolgamot G, Hill L, Zacharias K, Rogers A, Nix S, Schnell N. Abstract P3-13-20: Use of a 3-D bioabsorbable tissue marker in 61 patients over two years. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-13-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast conservation surgery (BCS) may preserve the breast but many women have less than optimal cosmetic outcomes. Increasingly, this has been addressed by the use of oncoplastic reconstruction.Now, targeting radiation treatment for boost or partial breast irradiation (PBI) using the seroma has become more difficult due to the adjacent tissue rearrangement and resultant “benign” seromas. Since the radiation dose generated increases by the third power of the radius (r3), there is a need to accurately focus radiation therapy to avoid chronic radiation side effects.We have used a 3-dimensional bioabsorbable tissue marker to accurately target the tumor bed while excluding inadvertent seromas caused by oncoplastic procedures. We report on tissue marker implantation on 61 consecutive breast conservation patients in regards to targeting, impact on cosmesis, imaging followup, ease of re-excision, as well as side effects and patient satisfaction.
METHODS: Consecutive lumpectomy patients who were candidates for targeted radiation therapy were considered for implantation with the 3-D bioabsorbable marker from May 2014 to June 2016. The tissue marker has a fixed array of 6 titanium clips and was sutured to the site of the excised breast cancer during lumpectomy.The framework of the implant resorbs slowly over time, while the clips remain permanently. All patients had oncoplastic reconstruction with total implant coverage. The marker was utilized for boost or partial breast irradiation (PBI) planning or treatment targeting. Data includes patient demographics, breast size, tumor characteristics, surgical and radiotherapy techniques, follow-up imaging, cosmesis and patient satisfaction.
Results:Data on 61 patients with median follow-up 12.7 months was analyzed (range 1.5–25.5). Median age was 62.4 years (range 33-74), 5 of women were postmenopausal and 15% had comorbidities. Cancer histology was in-situ (13%), invasive ductal (84%), invasive lobular (3%) of sizes T0 (13%), T1 (59%), T2 (25%), T3-4 (3%). Laterality and tumor location within the breast were typical. Re-excisions occurred in 11% of patients. No infections occurred in the postoperative period. One infection occurred with chemotherapy and another with repeated aspirations of oncoplastic area.No device was removed for infection, misplacement or patient-generated concerns. No cancer recurrences have been reported. Size of device used reflected size of the tumor; 2X2cm (44%), 2X3cm (34%) and 3X3cm (20%). The device was utilized by radiation oncologists for boost or PBI planning and treatment. Data on ease of setup and boost planning is being collected. Mammography at one year demonstrated marker clips coalescing as the bioabsorbable device dissolves. Evaluation of cosmetic appearance has shown good to excellent cosmesis as judged separately by both physicians and patients (92% and 94%).
Conclusions: Initial experience with 61 patients implanted with a novel 3-D absorbable device prospectively followed for an average of 12 months can be used in an array of breast cancer patients without device specific morbidity. Good to excellent cosmesis may be related to the addition of volume to the lumpectomy bed not seen with rearrangement of existing tissues.
Citation Format: Kaufman CS, Hall W, Behrndt V, Wolgamot G, Hill L, Zacharias K, Rogers A, Nix S, Schnell N. Use of a 3-D bioabsorbable tissue marker in 61 patients over two years [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-13-20.
Collapse
Affiliation(s)
- CS Kaufman
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - W Hall
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - V Behrndt
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - G Wolgamot
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - L Hill
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - K Zacharias
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - A Rogers
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - S Nix
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| | - N Schnell
- University of Washington, Bellingham, WA; Bellingham Regional Breast Center, Bellingham, WA; Northwest Radiation Oncology Associates, Bellingham, WA; Mt. Baker Imaging, Bellingham, WA; Northwest Pathologists, Bellingham, WA; Bellingham Ambulatory Surgery Center, Bellingham, WA
| |
Collapse
|
20
|
Chen X, Schott D, Song Y, Li D, Hall W, Erickson B, Li X. SU-F-R-50: Radiation-Induced Changes in CT Number Histogram During Chemoradiation Therapy for Pancreatic Cancer. Med Phys 2016. [DOI: 10.1118/1.4955821] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
21
|
Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AMB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin Infect Dis 2015; 62:655-663. [PMID: 26620652 PMCID: PMC4741360 DOI: 10.1093/cid/civ963] [Citation(s) in RCA: 118] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 11/06/2015] [Indexed: 11/13/2022] Open
Abstract
Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors. Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. Methods. Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)–infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. Results. The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%–9.5%) in 2008–2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. Conclusions. Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
Collapse
Affiliation(s)
- L Marije Hofstra
- Luxembourg Institute of Health, Luxembourg.,Department of Virology, University Medical Center Utrecht, The Netherlands
| | | | - Jan Albert
- Karolinska Institute, Solna.,Karolinska University Hospital, Stockholm, Sweden
| | - Ivailo Alexiev
- National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
| | - Federico Garcia
- Complejo Hospitalario Universitario de Granada, Instituto de Investigación IBS Granada; on behalf of Cohorte de Adultos de la Red de Investigación en SIDA, Spain
| | | | | | | | - Danail Beshkov
- National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
| | | | - Diane Descamps
- AP-HP Groupe hospitalier Bichat-Claude Bernard, IAME INSERM UMR 1137, Université Paris Diderot Sorbonne Paris Cité, Paris, France
| | | | | | | | | | | | | | - Kirsi Liitsola
- Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland
| | - Marek Linka
- National Reference Laboratory for HIV/AIDS, National Institute of Public Health, Prague, Czech Republic
| | - Orna Mor
- National HIV Reference Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | | | - Dan Otelea
- National Institute for Infectious Diseases "Prof. dr. Matei Bals", Bucharest, Romania
| | | | | | - Mario Poljak
- Faculty of Medicine, Slovenian HIV/AIDS Reference Centre, University of Ljubljana, Slovenia
| | | | - Anders Sönnerborg
- Karolinska Institute, Solna.,Karolinska University Hospital, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Hoban B, Larance B, Gisev N, Nielsen S, Cohen M, Bruno R, Shand F, Lintzeris N, Hall W, Farrell M, Degenhardt L. The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J Clin Pract 2015; 69:1366-76. [PMID: 26268890 DOI: 10.1111/ijcp.12716] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Accepted: 07/22/2015] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND The regular use of simple analgesics in addition to opioids such as paracetamol (or acetaminophen) is recommended for persistent pain to enhance analgesia. Few studies have examined the frequency and doses of paracetamol among people with chronic non-cancer pain including use above the recommended maximum daily dose. AIMS To assess (i) the prevalence of paracetamol use among people with chronic non-cancer pain prescribed opioids, (ii) assess the prevalence of paracetamol use above the recommended maximum daily dose and (iii) assess correlates of people who used paracetamol above the recommended maximum daily dose including: age, gender, income, education, pain severity and interference, use of paracetamol/opioid combination analgesics, total opioid dose, depression, anxiety, pain self-efficacy or comorbid substance use, among people prescribed opioids for chronic non-cancer pain. METHODS This study draws on baseline data collected for the Pain and Opioids IN Treatment (POINT) study and utilises data from 962 interviews and medication diaries. The POINT study is national prospective cohort of people with chronic non-cancer pain prescribed opioids. Participants were recruited from randomly selected pharmacies across Australia. RESULTS Sixty-three per cent of the participants had used paracetamol in the past week (95% CI = 59.7-65.8). Among the paracetamol users 22% (95% CI = 19.3-24.6) had used paracetamol/opioid combination analgesics and 4.8% (95% CI = 3.6-6.3) had used paracetamol above the recommended maximum daily dose (i.e. > 4000 mg/day). Following binomial logistic regression (χ(2) = 25.98, df = 10, p = 0.004), people who had taken above the recommended maximum daily dose were less likely to have low income (AOR = 0.52, 95% CI = 0.27-0.99), more likely to use paracetamol/opioid combination analgesics (AOR = 2.01, 95% CI = 1.02-3.98) and more likely to take a higher opioid dose (AOR = 1.00, 95% CI = 1.00-1.01). CONCLUSION The majority of people with chronic non-cancer pain prescribed opioids report using paracetamol appropriately. High income, use of paracetamol/opioid combination analgesics and higher opioid dose were independently associated with paracetamol use above the recommended maximum daily dose.
Collapse
Affiliation(s)
- B Hoban
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - B Larance
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - N Gisev
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - S Nielsen
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- The Langton Centre, South East Sydney Local Health District (SESLHD), Drug and Alcohol Services, Surry Hills, NSW, Australia
| | - M Cohen
- St Vincent's Clinical School, UNSW Australia, Darlinghurst, NSW, Australia
| | - R Bruno
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- School of Psychology, University of Tasmania, Hobart, TAS, Australia
| | - F Shand
- Black Dog Institute, Prince of Wales Hospital, Randwick, NSW, Australia
| | - N Lintzeris
- The Langton Centre, South East Sydney Local Health District (SESLHD), Drug and Alcohol Services, Surry Hills, NSW, Australia
- Sydney Medical School, Sydney University, Camperdown, NSW, Australia
| | - W Hall
- Centre for Youth Substance Abuse Research, University of Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
| | - M Farrell
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - L Degenhardt
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia
- Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, Australia
- Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA
| |
Collapse
|
23
|
Dalah E, Tai A, Oshima K, Hall W, Erickson B, Li X. TU-G-BRA-06: PET-Based Treatment Response Assessement for Neoadjuvent Chemoradiation for Pancreatic Adenocarcinoma. Med Phys 2015. [DOI: 10.1118/1.4925756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
24
|
Dalah E, Tai A, Oshima K, Hall W, Knechtges P, Erickson B, Li X. SU-E-J-271: Correlation of CT Number Change with Radiation Treatment Response for Pancreatic Cancer. Med Phys 2015. [DOI: 10.1118/1.4924357] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
25
|
Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther 2015; 97:607-15. [PMID: 25777798 DOI: 10.1002/cpt.110] [Citation(s) in RCA: 110] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 03/05/2015] [Indexed: 11/10/2022]
Abstract
A major challenge in assessing the public health impact of legalizing cannabis use in Colorado and Washington State is the absence of any experience with legal cannabis markets. The Netherlands created a de facto legalized cannabis market for recreational use, but policy analysts disagree about how it has affected rates of cannabis use. Some US states have created de facto legal supply of cannabis for medical use. So far this policy does not appear to have increased cannabis use or cannabis-related harm. Given experience with more liberal alcohol policies, the legalization of recreational cannabis use is likely to increase use among current users. It is also likely that legalization will increase the number of new users among young adults but it remains uncertain how many may be recruited, within what time frame, among which groups within the population, and how many of these new users will become regular users.
Collapse
Affiliation(s)
- W Hall
- Centre for Youth Substance Abuse Research, University of Queensland, Herston, Australia.,Addiction Policy, National Addiction Centre, Kings College, London, UK
| | - M Weier
- Centre for Youth Substance Abuse Research, University of Queensland, Herston, Australia
| |
Collapse
|
26
|
Riggall K, Forlini C, Carter A, Weier M, Hall W, Meinzer M. Researchers' perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey. Brain Stimul 2015. [DOI: 10.1016/j.brs.2015.01.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
27
|
Reid CT, De Gascun C, Hall W, Collins P, Lally A, Kirby B. Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary? Br J Dermatol 2014; 169:1319-21. [PMID: 24032395 DOI: 10.1111/bjd.12598] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/17/2013] [Indexed: 01/11/2023]
Abstract
BACKGROUND Screening for hepatitis C virus (HCV) prior to the commencement of antitumour necrosis factor (anti-TNF)-α therapies for dermatological disease is recommended for all patients. OBJECTIVES To determine the incidence of HCV infection among dermatology patients who were screened for HCV infection prior to commencing anti-TNF-α therapies. METHODS We reviewed the HCV infection status of all patients attending our dermatology department who had been tested for evidence of HCV infection between January 2005 and November 2012. We identified patients who had been tested as part of routine screening prior to commencing anti-TNF-α therapy using dermatology departmental records. RESULTS In total, 215 patients were screened for HCV infection prior to commencing anti-TNF-α therapies. Among this group, 143 patients (66·5%) were male and 72 (33·5%) were female. None of these patients tested positive for active HCV infection. One patient tested positive for HCV antibody with negative HCV antigen and HCV RNA. This indicated previous HCV infection that had cleared. This patient had abnormal liver function tests and a history of alcohol excess. CONCLUSIONS There were no cases of active HCV infection diagnosed through pretreatment anti-TNF-α screening in our department, which is located in a low-prevalence area for HCV infection. In view of the lack of evidence of harm associated with anti-TNF-α use in HCV-infected patients, we propose that screening for HCV infection in low-prevalence areas should be targeted to those with pre-existing risk factors. This is consistent with current guidelines from the Royal College of General Practitioners. Targeted screening rather than universal screening may be a safe and cost-effective option among patients being evaluated for anti-TNF-α therapies.
Collapse
Affiliation(s)
- C T Reid
- Department of Dermatology, Saint Vincent's University Hospital, Elm Park, Dublin 4, Ireland
| | | | | | | | | | | |
Collapse
|
28
|
Rai D, Hall W, Bebbington P, Skapinakis P, Hassiotis A, Weich S, Meltzer H, Moran P, Brugha T, Strydom A, Farrell M. Estimated verbal IQ and the odds of problem gambling: a population-based study. Psychol Med 2014; 44:1739-1749. [PMID: 24007680 DOI: 10.1017/s0033291713002195] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND The neurocognitive deficits and other correlates of problem gambling are also observable in individuals with lower cognitive abilities, suggesting that a low IQ may be a determinant of problem gambling. There has been very little research into this possibility. This study aimed to investigate the characteristics associated with problem gambling in a large population-based study in England, with a particular focus on IQ. METHOD The Adult Psychiatric Morbidity Survey (APMS) 2007 comprised detailed interviews with 7403 individuals living in private households in England. Problem gambling was ascertained using a questionnaire based on DSM-IV criteria. Verbal IQ was estimated using the National Adult Reading Test (NART). Confounders included socio-economic and demographic factors, common mental disorders, impulsivity, smoking, and hazardous drug and alcohol use. RESULTS More than two-thirds of the population reported engaging in some form of gambling in the previous year, but problem gambling was rare [prevalence 0.7%, 95% confidence interval (CI) 0.5-1.0]. The odds of problem gambling doubled with each standard deviation drop in estimated verbal IQ [adjusted odds ratio (OR) 2.1, 95% CI 1.3-3.4, p = 0.003], after adjusting for other characteristics associated with problem gambling including age, sex, socio-economic factors, drug and alcohol dependence, smoking, impulsivity and common mental disorders. There was no strong relationship observed between IQ and non-problem gambling. CONCLUSIONS People with lower IQs may be at a higher risk of problem gambling. Further work is required to replicate and study the mechanisms behind these findings, and may aid the understanding of problem gambling and inform preventative measures and interventions.
Collapse
Affiliation(s)
- D Rai
- Centre for Mental Health, Addiction and Suicide Research, School of Social and Community Medicine, University of Bristol, UK
| | - W Hall
- UQ Centre for Clinical Research, The University of Queensland, Royal Brisbane and Women's Hospital, Queensland, Australia
| | | | - P Skapinakis
- Centre for Mental Health, Addiction and Suicide Research, School of Social and Community Medicine, University of Bristol, UK
| | | | - S Weich
- Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, UK
| | - H Meltzer
- Department of Health Sciences, College of Medicine, Biological Sciences and Psychology, University of Leicester, UK
| | - P Moran
- Institute of Psychiatry, King's College London, UK
| | - T Brugha
- Department of Health Sciences, College of Medicine, Biological Sciences and Psychology, University of Leicester, UK
| | - A Strydom
- UCL Mental Health Sciences Unit, London, UK
| | - M Farrell
- National Drug and Alcohol Research Centre, University of New South Wales, Australia
| |
Collapse
|
29
|
Hall W, Neumann E. Fresh Pork and Porcine Reproductive and Respiratory Syndrome Virus: Factors Related to the Risk of Disease Transmission. Transbound Emerg Dis 2013; 62:350-66. [PMID: 24016101 DOI: 10.1111/tbed.12163] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Indexed: 11/27/2022]
Abstract
Porcine reproductive and respiratory syndrome virus (PRRS) is a highly infectious virus. Experimentally, the disease can be induced in naïve pigs by the oral, intranasal and intramuscular routes. Depending on the virulence of the strain of the virus and the age of the pig, peak viremia can occur within 7 days of infection, and live virus can be isolated from blood or lymph nodes for several months post-infection. Young pigs tend to develop higher titres of viremia than older pigs infected by the same route and dose with the same strain of virus. Porcine reproductive and respiratory syndrome virus survives in pork harvested from infected pigs for extended periods at temperatures of -20 or -70°C. In experimentally infected pigs, survival of PRRS virus in muscle held at 4°C has been demonstrated for at least 7 days, and infectivity of the virus in these samples was confirmed by bioassay. The optimal pH range for the survival of PRRS virus is thought to be 6.0 to 7.5. The elevated pH of non-meat tissues (generally one pH unit higher) is likely to favour extended survival of PRRS virus in pig carcasses from which all superficial and deep lymph nodes have not been removed. It is likely that exsanguinated carcasses held at 4°C retain sufficient blood or lymph tissue to contain infective doses of PRRS virus. Porcine reproductive and respiratory syndrome virus is rapidly inactivated by heat, providing a predictable method to ensure that pork tissues are free of viable virus and feeding of cooked swill or garbage should not constitute a risk to pigs. While the probability of viable PRRS virus being present in a pig carcass may be low, the risk is not zero. The importation of raw pork into countries where PRRS is not endemic represents a hazard with potentially severe economic consequences.
Collapse
Affiliation(s)
- W Hall
- William Hall and Associates, Googong, NSW, Australia
| | - E Neumann
- EpiCentre, Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Palmerston North, New Zealand
| |
Collapse
|
30
|
Ikebe E, Kawaguchi A, Tezuka K, Taguchi S, Hirose S, Matsumoto T, Mitsui T, Senba K, Nishizono A, Hori M, Hasegawa H, Yamada Y, Ueno T, Tanaka Y, Sawa H, Hall W, Minami Y, Jeang KT, Ogata M, Morishita K, Hasegawa H, Fujisawa J, Iha H. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice. Blood Cancer J 2013; 3:e132. [PMID: 23955587 PMCID: PMC3763384 DOI: 10.1038/bcj.2013.30] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2012] [Revised: 06/24/2013] [Accepted: 06/28/2013] [Indexed: 12/29/2022] Open
Abstract
In the peripheral blood leukocytes (PBLs) from the carriers of the human T-lymphotropic virus type-1 (HTLV-1) or the patients with adult T-cell leukemia (ATL), nuclear factor kappaB (NF-κB)-mediated antiapoptotic signals are constitutively activated primarily by the HTLV-1-encoded oncoprotein Tax. Tax interacts with the I κB kinase regulatory subunit NEMO (NF-κB essential modulator) to activate NF-κB, and this interaction is maintained in part by a molecular chaperone, heat-shock protein 90 (HSP90), and its co-chaperone cell division cycle 37 (CDC37). The antibiotic geldanamycin (GA) inhibits HSP90's ATP binding for its proper interaction with client proteins. Administration of a novel water-soluble and less toxic GA derivative, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG), to Tax-expressing ATL-transformed cell lines, C8166 and MT4, induced significant degradation of Tax. 17-DMAG also facilitated growth arrest and cellular apoptosis to C8166 and MT4 and other ATL cell lines, although this treatment has no apparent effects on normal PBLs. 17-DMAG also downregulated Tax-mediated intracellular signals including the activation of NF-κB, activator protein 1 or HTLV-1 long terminal repeat in Tax-transfected HEK293 cells. Oral administration of 17-DMAG to ATL model mice xenografted with lymphomatous transgenic Lck-Tax (Lck proximal promoter-driven Tax transgene) cells or HTLV-1-producing tumor cells dramatically attenuated aggressive infiltration into multiple organs, inhibited de novo viral production and improved survival period. These observations identified 17-DMAG as a promising candidate for the prevention of ATL progression.
Collapse
Affiliation(s)
- E Ikebe
- Department of Infectious Diseases, Faculty of Medicine, Oita University, Yufu, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Phillips CM, Hall W, Gjelstad IMF, Lairon D, Saris W, Kieć-Wilk B, Karlström B, Drevon CA, Defoort C, Blaak EE, Dembinska-Kieć A, Risérus U, Lovegrove JA, Roche HM, Lopez-Miranda J. A gene variation (rs12691) in the CCAT/enhancer binding protein α modulates glucose metabolism in metabolic syndrome. Nutr Metab Cardiovasc Dis 2013; 23:417-423. [PMID: 22269963 DOI: 10.1016/j.numecd.2011.09.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2011] [Revised: 09/20/2011] [Accepted: 09/23/2011] [Indexed: 12/12/2022]
Abstract
BACKGROUND AND AIMS CCAAT/enhancer-binding protein alpha (CEBPA) is a transcription factor involved in adipogenesis and energy homeostasis. Caloric restriction reduces CEBPA protein expression in patients with metabolic syndrome (MetS). A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides. Our objective was to assess the effects of rs12691 in glucose metabolism in Metabolic Syndrome (MetS) patients. METHODS AND RESULTS Glucose metabolism was assessed by static (glucose, insulin, adiponectin, leptin and resistin plasma concentrations) and dynamic (disposition index, insulin sensitivity index, HOMA-IR and acute insulin response to glucose) indices, performed at baseline and after 12 weeks of 4 dietary interventions (high saturated fatty acid (SFA), high monounsaturated fatty acid (MUFA), low-fat and low-fat-high-n3 polyunsaturated fatty acid (PUFA)) in 486 subjects with MetS. Carriers of the minor A allele of rs12691 had altered disposition index (p = 0.0003), lower acute insulin response (p = 0.005) and a lower insulin sensitivity index (p = 0.025) indicating a lower insulin sensitivity and a lower insulin secretion, at baseline and at the end of the diets. Furthermore, A allele carriers displayed lower HDL concentration. CONCLUSION The presence of the A allele of rs12691 influences glucose metabolism of MetS patients.
Collapse
Affiliation(s)
- J Delgado-Lista
- Lipids and Atherosclerosis Unit, Department of Medicine, IMIBIC/Hospital Universitario Reina Sofía/Universidad de Córdoba, Cordoba, Spain; CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Morphett K, Lucke J, Gartner C, Carter A, Meurk C, Hall W. Public Attitudes Toward the Treatment of Nicotine Addiction. Nicotine Tob Res 2013; 15:1617-22. [DOI: 10.1093/ntr/ntt037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
33
|
Şah M, Hall W. A personalized semantic portal for enhanced user support. NEW REV HYPERMEDIA M 2013. [DOI: 10.1080/13614568.2012.702132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
34
|
Fitzpatrick G, Ward M, Ennis O, Johnson H, Cotter S, Carr MJ, O Riordan B, Waters A, Hassan J, Connell J, Hall W, Clarke A, Murphy H, Fitzgerald M. Use of a geographic information system to map cases of measles in real-time during an outbreak in Dublin, Ireland, 2011. ACTA ACUST UNITED AC 2012; 17. [PMID: 23231894 DOI: 10.2807/ese.17.49.20330-en] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In 2011, there was a large measles outbreak in Dublin. Nationally 285 cases were notified to the end of December 2011, and 250 (88%) were located in the Dublin region. After the first case was notified in week 6, numbers gradually increased, with 25 notified in June and a peak of 53 cases in August. Following public health intervention including a measles-mumps-rubella (MMR) vaccination campaign, no cases were reported in the Dublin region in December 2011. Most cases (82%) were children aged between 6 months and 14 years, and 46 cases (18%) were under 12 months-old. This is the first outbreak in Dublin to utilise a geographic information system for plotting measles cases on a digital map in real time. This approach, in combination with the analysis of case notifications, assisted the department of public health in demonstrating the extent of the outbreak. The digital mapping documented the evolution of two distinct clusters of 87 (35%) cases. These measles cases were infected with genotype D4-Manchester recently associated with large outbreaks across Europe. The two clusters occurred in socio-economically disadvantaged areas and were attributable to inadequate measles vaccination coverage due in part to the interruption of a school-based MMR2 vaccination programme.
Collapse
Affiliation(s)
- G Fitzpatrick
- Department of Public Health, Health Service Executive (HSE) East, Dr Steeven's Hospital, Dublin, Ireland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Prabhu R, Liebman L, Wojno T, Hayek B, Hall W, Crocker I. Clinical Outcomes of Radiation Therapy as Initial Local Therapy for Graves' Ophthalmopathy and Predictors of the Need for Postradiation Therapy Decompressive Surgery. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
36
|
Farrell M, Hall W. Griffith Edwards. Assoc Med J 2012. [DOI: 10.1136/bmj.e7234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Abstract
A meta-analysis of randomized and controlled evaluations of the efficacy of smoking cessation interventions compared 146 estimates of the difference in abstinence rates between treated and control conditions (effect sizes) from 85 publications. Simple advice to quit and other brief intervention techniques, nicotine chewing gum and behavioural techniques were all found to be significantly better than relevant control conditions in promoting abstinence, although the results were not homogeneous. In five studies of acupuncture compared with control, consistent results were found showing no benefit for acupuncture.
Collapse
Affiliation(s)
- A J Baillie
- National Drug and Alcohol Research Centre, University of New South Wales, Kensington, NSW
| | | | | | | |
Collapse
|
38
|
Abstract
This paper uses the New South Wales experience with methadone maintenance treatment in prison to address the question: should methadone maintenance treatment be provided in Australian prisons for opioid-dependent prisoners? First, it outlines three rationales for providing drug dependence treatment in prisons: as a way of giving prisoners access to community-based forms of drug treatment in the prison setting; as a measure to reduce recidivism in opioid-dependent prisoners; and as a measure to prevent the transmission of HIV and other infectious diseases within prisons, and to the sexual partners of prisoners on their release. Secondly, it reviews the kind of research evidence that supports the effectiveness of community-based methadone maintenance treatment in Australia. Thirdly, the effectiveness of the New South Wales Prison Methadone Programme, one of the few prison-based methadone programmes in the world, is evaluated in the light of the available research evidence.
Collapse
Affiliation(s)
- W Hall
- National Drug and Alcohol Research Centre, PO Box 1, Kensington, NSW, 2033, Australia
| | | | | |
Collapse
|
39
|
Pallin M, O'Sullivan C, Dodd JD, McCreery K, Brett F, Farrell M, O'Brien D, Hall WW, Tubridy NJ, Keane MP. A case of progressive multifocal leukoencephalopathy in a patient with sarcoidosis. QJM 2012; 105:1011-6. [PMID: 21893584 DOI: 10.1093/qjmed/hcr154] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Pallin
- St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Batth S, Daly M, Cui J, Hall W, Li Y, Beckett L, Purdy J, Bobinski M, Dublin A, Chen A. Anatomical Contouring Guidelines and Dosimetric Analysis of Brachial Plexus Segments for Patients Treated by Intensity-Modulated Radiotherapy for Head and Neck Cancer. Skull Base Surg 2012. [DOI: 10.1055/s-0032-1313954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Leung J, Gartner C, Hall W, Lucke J, Dobson A. A longitudinal study of the bi-directional relationship between tobacco smoking and psychological distress in a community sample of young Australian women. Psychol Med 2012; 42:1273-1282. [PMID: 22011372 DOI: 10.1017/s0033291711002261] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Tobacco smoking and poor mental health are both prevalent and detrimental health problems in young women. The temporal relationship between the two variables is unclear. We investigated the prospective bi-directional relationship between smoking and mental health over 13 years. METHOD Participants were a randomly selected community sample of 10 012 young women with no experience of pregnancy, aged 18-23 years at baseline (1996) from the Australian Longitudinal Study on Women's Health. Follow-up surveys over 13 years were completed in 2000, 2003, 2006 and 2009, allowing for five waves of data. Measures included self-reported smoking and mental health measured by the Mental Health Index from the 36-item short-form health questionnaire and the 10-item Center for Epidemiologic Studies Depression Scale. Sociodemographic control variables included marital status, education level and employment status. RESULTS A strong cross-sectional dose-response relationship between smoking and poor mental health was found at each wave [odds ratio (OR) 1.41, 95% confidence intervals (CI) 1.17-1.70 to OR 2.27, 95% CI 1.82-2.81]. Longitudinal results showed that women who smoked had 1.21 (95% CI 1.06-1.39) to 1.62 (95% CI 1.24-2.11) times higher odds of having poor mental health at subsequent waves. Women with poor mental health had 1.12 (95% CI 1.17-1.20) to 2.11 (95% CI 1.68-2.65) times higher odds of smoking at subsequent waves. These results held after adjusting for mental health history and smoking history and sociodemographic factors. Correlation analysis and structural equation modelling results were consistent in showing that both directions of the relationship were statistically significant. CONCLUSIONS The association between poor mental health and smoking in young women appeared to be bi-directional.
Collapse
Affiliation(s)
- J Leung
- School of Population Health, University of Queensland, Brisbane, Australia.
| | | | | | | | | |
Collapse
|
42
|
|
43
|
Prabhu R, Hadjipanayis C, Shu H, Hall W, Raore B, Olson J, Curran W, Oyesiku N, Crocker I. Current Dosing Paradigm For Stereotactic Radiosurgery Alone Following Surgical Resection of Brain Metastases Needs To Be Optimized For Improved Local Control. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
O'Halloran JA, De Gascun CF, Dunford L, Carr MJ, Connell J, Howard R, Hall WW, Lambert JS. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. J Clin Virol 2011; 52:151-4. [PMID: 21802353 DOI: 10.1016/j.jcv.2011.06.020] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2011] [Revised: 06/19/2011] [Accepted: 06/30/2011] [Indexed: 12/11/2022]
Affiliation(s)
- J A O'Halloran
- Mater Misericordiae University Hospital, Dublin 7, Ireland.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Vogel B, Pan LL, Konopka P, Günther G, Müller R, Hall W, Campos T, Pollack I, Weinheimer A, Wei J, Atlas EL, Bowman KP. Transport pathways and signatures of mixing in the extratropical tropopause region derived from Lagrangian model simulations. ACTA ACUST UNITED AC 2011. [DOI: 10.1029/2010jd014876] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
46
|
Taylor S, Bain D, Whitington M, Harris J, Livingstone W, Pennington K, Hall W. Evaluation of an online advanced life support program. Aust Crit Care 2011. [DOI: 10.1016/j.aucc.2010.12.056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
47
|
Molloy A, Kinsella K, Turbridy N, Hutchinson M, Duggan M, De Gascun CF, Lonergan R, Stack J, Hall W. POI09 Trends in BK and JC polyomavirus and relationship to CD4+/CD8+ ratio in patients with relapsing remitting multiple sclerosis on natalizumab therapy. Journal of Neurology, Neurosurgery & Psychiatry 2010. [DOI: 10.1136/jnnp.2010.226340.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Schemann AK, Hernández-Jover M, Hall W, Holyoake PK, Toribio JALML. Assessment of current disease surveillance activities for pigs post-farmgate in New South Wales. Aust Vet J 2010; 88:75-83. [PMID: 20402689 DOI: 10.1111/j.1751-0813.2009.00543.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Evaluate current disease surveillance activities at saleyards and abattoirs in New South Wales (NSW) in order to establish the prevalence of clinical anomalies in pigs at different sites and to compare the sensitivity of detecting anomalies inside versus outside of pens. PROCEDURE Routine inspections of pigs by staff and government inspectors were observed at two saleyards and two abattoirs in NSW during three visits over a 2-month period (January 2008-March 2008). All pigs presented for sale or slaughter were examined for 19 clinical anomalies from either the side of the pen or while animals were moving outside the pen, with data being combined to give an assumed 'gold standard'. We compared the prevalence of anomalies among animals at the four sites using logistic regression, as well as the sensitivity of detection of the two inspection methods. RESULTS Frequency and methodology of routine inspection varied among sites. Of the 7747 pigs inspected, 822 (10.6%) showed at least one clinical anomaly. There was moderate agreement between detecting anomalies in penned pigs versus while being moved. Pigs at one abattoir exhibited significantly fewer anomalies than pigs at the other sites. CONCLUSION The prevalence of anomalies among pigs at saleyards and abattoirs in NSW was relatively high ( approximately 10%). Weaknesses in current disease surveillance activities for pigs post-farmgate have been identified. Increased regulation, surveillance training and modification of standard operational procedures for inspection have the potential to improve the current system.
Collapse
Affiliation(s)
- A K Schemann
- Faculty of Veterinary Science, The University of Sydney, 425 Werombi Road, Camden, New South Wales 2570, Australia.
| | | | | | | | | |
Collapse
|
49
|
MacNeil A, Lederman E, Reynolds MG, Ragade NJ, Talken R, Friedman D, Hall W, Shwe T, Li Y, Zhao H, Smith S, Davidson W, Hughes C, Damon IK. Diagnosis of Bovine-Associated Parapoxvirus Infections in Humans: Molecular and Epidemiological Evidence. Zoonoses Public Health 2010; 57:e161-4. [DOI: 10.1111/j.1863-2378.2009.01317.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
|